RIPK3 Protein, Human (P.pastoris, His)

RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3 Protein, Human (P.pastoris, His) is the recombinant human-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of RIPK3 Protein, Human (P.pastoris, His) is 518 a.a., with molecular weight of ~64 kDa.

RIPK3, a serine/threonine-protein kinase, orchestrates both necroptosis and apoptosis, two distinct forms of programmed cell death. Necroptosis, triggered by death-inducing TNF-alpha family members and activated by ZBP1, involves RIPK3-mediated phosphorylation of MLKL, leading to membrane damage and calcium influx. Additionally, in response to orthomyxovirus infection, nuclear RIPK3, prompted by ZBP1 activation, phosphorylates MLKL, causing nuclear envelope disruption and DNA leakage. RIPK3 also regulates apoptosis, dependent on RIPK1, FADD, and CASP8, independently of MLKL and RIPK3 kinase activity. In certain cell types, RIPK3 restricts viral replication through cell death-independent responses. In the context of Zika virus infection in neurons, RIPK3, along with ZBP1, promotes a death-independent transcriptional program, upregulating ACOD1/IRG1 and itaconate production, inhibiting succinate dehydrogenase, and suppressing viral genome replication. RIPK3 enhances the activity of metabolic enzymes (GLUL, GLUD1, PYGL), potentially influencing the tricarboxylic acid cycle and oxidative phosphorylation. During herpes simplex virus 1 infection, RIPK3 forms heteromeric amyloid structures with HHV-1 protein RIR1/ICP6, potentially inhibiting RIPK3-mediated necroptosis, enabling viral evasion of host cell death pathways.

The enzyme activity of this recombinant protein is testing in progress, we cannot offer a guarantee yet.

Human

P. pastoris

N-6*His

Q9Y572 (M1-K518)

11035  [NCBI]

MSCVKLWPSGAPAPLVSIEELENQELVGKGGFGTVFRAQHRKWGYDVAVKIVNSKAISREVKAMASLDNEFVLRLEGVIEKVNWDQDPKPALVTKFMENGSLSGLLQSQCPRPWPLLCRLLKEVVLGMFYLHDQNPVLLHRDLKPSNVLLDPELHVKLADFGLSTFQGGSQSGTGSGEPGGTLGYLAPELFVNVNRKASTASDVYSFGILMWAVLAGREVELPTEPSLVYEAVCNRQNRPSLAELPQAGPETPGLEGLKELMQLCWSSEPKDRPSFQECLPKTDEVFQMVENNMNAAVSTVKDFLSQLRSSNRRFSIPESGQGGTEMDGFRRTIENQHSRNDVMVSEWLNKLNLEEPPSSVPKKCPSLTKRSRAQEEQVPQAWTAGTSSDSMAQPPQTPETSTFRNQMPSPTSTGTPSPGPRGNQGAERQGMNWSCRTPEPNPVTGRPLVNIYNCSGVQVGDNNYLTMQQTTALPTWGLAPSGKGRGLQHPPPVGSQEGPKDPEAWSRPQGWYNHSGK

Approximately 64 kDa

Greater than 90% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized after extensive dialysis against solution in PBS, 6% Trehalose, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.